GLUE COO exercises options, sells 2,175 shares

Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an exercise-and-sale transaction in company stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an exercise-and-sale transaction in company stock. She exercised stock options to acquire 2,175 shares of common stock at $3.98 per share, then sold 2,175 shares in an open-market transaction at $20.00 per share.

After these transactions, she directly holds 62,371 shares of common stock and 31,298 stock options. The filing notes that the trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,175 shares ($35K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Champoux Jennifer

Role Chief Operating Officer

Sold 2,175 shs ($44K)

Approx. gross sale proceeds $44K

Approx. exercise cost $9K

Approx. pre-tax spread $35K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,175	$0.00	$0.00
Exercise	Common Stock	2,175	$3.98	$9K
Sale	Common Stock	2,175	$20.00	$44K

Holdings After Transaction: Stock Option (Right to Buy) — 31,298 contracts (Direct); Common Stock — 62,371 shares (Direct)

Footnotes (2)

F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.
F2. 25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 2,175 shares Sale price: $20.00 per share Options exercised: 2,175 shares +5 more

8 metrics

Shares sold 2,175 shares Open-market sale of common stock at $20.00 on June 23, 2026

Sale price $20.00 per share Price for 2,175 common shares sold on June 23, 2026

Options exercised 2,175 shares Shares acquired via stock option exercise on June 23, 2026

Option exercise price $3.98 per share Exercise or conversion price of stock option (right to buy)

Shares held after 62,371 shares Total common stock directly owned following transactions

Options remaining 31,298 options Stock option position following the 2,175-share exercise

10b5-1 plan adoption date February 19, 2026 Date COO adopted Rule 10b5-1 trading plan governing these trades

Option expiration June 3, 2034 Expiration date of the stock option exercised for 2,175 shares

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), Exercise or conversion of derivative security, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"transaction_type": "non-derivative""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GLUE COO Jennifer Champoux report?

Jennifer Champoux reported exercising options for 2,175 Monte Rosa Therapeutics shares at $3.98 and selling 2,175 shares at $20.00. The transactions reflect an exercise-and-sell pattern, where options are converted into shares and those shares are then sold in the market.

How many Monte Rosa Therapeutics (GLUE) shares does the COO hold after this Form 4?

Following the reported transactions, COO Jennifer Champoux directly holds 62,371 shares of Monte Rosa Therapeutics common stock. She also has 31,298 stock options remaining after the 2,175-share option exercise disclosed in the Form 4 filing for the same date.

At what prices did the GLUE COO exercise options and sell shares?

Jennifer Champoux exercised stock options at an exercise price of $3.98 per share and sold 2,175 Monte Rosa Therapeutics shares at $20.00 per share. These prices highlight the difference between the option strike price and the market sale price on the transaction date.

Were the GLUE insider transactions under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on February 19, 2026. Such pre-arranged plans schedule trades in advance, making the timing more routine and less indicative of short-term views on the stock.

What type of derivative security did the GLUE COO exercise?

She exercised a “Stock Option (Right to Buy)” derivative security covering 2,175 shares of Monte Rosa Therapeutics common stock. The option carried a $3.98 exercise price and has an expiration date of June 3, 2034, according to the Form 4 disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/25/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Champoux Jennifer

(Last)

(First)

(Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON

MASSACHUSETTS

02118

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/23/2026		M⁽¹⁾		2,175	A	$3.98	64,546	D
Common Stock	06/23/2026		S⁽¹⁾		2,175	D	$20	62,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$3.98	06/23/2026		M⁽¹⁾			2,175	⁽²⁾	06/03/2034	Common Stock	2,175	$0	31,298	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

2. 25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Phil Nickson, Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR